Iktos and Pfizer Announce Collaboration on Artificial Intelligence for Drug Discovery Project - Actu IA

French start-up Iktos has announced a collaboration with Pfizer on the use of its artificial intelligence technology for drug design. This partnership comes in response to the considerable progress in the development of AI algorithms and computing power that has enabled the development of innovative approaches to small molecule drug design. Founded in 2016, Iktos develops generative AI technology in numerous collaborations with pharmaceutical and biotech companies. A fundamental aspect of the technology lies in the exploration of chemical space performed by generating compounds in silico under the constraints of the program's final objectives, rather than by screening compound libraries. As part of the collaboration, Pfizer has deployed Iktos' generative AI technology and is applying it to several small molecule research programs.